Pluristem Asset Resilience Ratio

Latest as of March 2022: 48.26%

Pluristem asset resilience ratio. Pluristem (PSTI) has an Asset Resilience Ratio of 48.26% as of March 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read PSTI current and long-term liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

ILA38.19 Million
≈ $102.38K USD Cash + Short-term Investments

Total Assets

ILA79.13 Million
≈ $212.14K USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of Pluristem (2014–2021)

Asset resilience ratio of Pluristem from 2014 to 2021. This chart shows how Pluristem's Asset Resilience Ratio has changed over time. See PSTI FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.

Liquid Assets Composition Over Time

This chart breaks down Pluristem's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see PSTI total asset value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ILA0.00 0%
Short-term Investments ILA38.19 Million 48.26%
Total Liquid Assets ILA38.19 Million 48.26%

Asset Resilience Insights

  • Very High Liquidity: Pluristem maintains exceptional liquid asset reserves at 48.26% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Pluristem Industry Peers by Asset Resilience Ratio

Compare Pluristem's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Hadasit Bio
TA:HDST
Biotechnology & Medical Research 57.00%
Purple Biotech Ltd
TA:KTOV
Biotechnology & Medical Research 0.01%
Peptron Inc
KQ:087010
Biotechnology & Medical Research 37.11%
Bioneer Corporation
KQ:064550
Biotechnology & Medical Research 14.92%
MEDIPOST Co. Ltd
KQ:078160
Biotechnology & Medical Research 0.72%
Cell Biotech Co. Ltd
KQ:049960
Biotechnology & Medical Research 54.84%
Macrogen Inc
KQ:038290
Biotechnology & Medical Research 3.56%
Panagene Inc
KQ:046210
Biotechnology & Medical Research 0.14%

Pluristem Asset Resilience Ratio by Year (2014–2021)

Pluristem asset resilience ratio by year from 2014 to 2021. The table below shows the annual Asset Resilience Ratio data for Pluristem.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2021-06-30 36.04% ILA33.71 Million
≈ $90.37K
ILA93.54 Million
≈ $250.77K
-21.21pp
2020-06-30 57.25% ILA37.51 Million
≈ $100.57K
ILA65.53 Million
≈ $175.69K
-5.35pp
2019-06-30 62.60% ILA19.60 Million
≈ $52.54K
ILA31.31 Million
≈ $83.94K
+8.49pp
2018-06-30 54.10% ILA21.08 Million
≈ $56.51K
ILA38.96 Million
≈ $104.45K
-2.91pp
2017-06-30 57.01% ILA21.40 Million
≈ $57.37K
ILA37.53 Million
≈ $100.63K
+0.45pp
2016-06-30 56.56% ILA25.98 Million
≈ $69.66K
ILA45.94 Million
≈ $123.17K
+13.40pp
2015-06-30 43.16% ILA29.42 Million
≈ $78.87K
ILA68.16 Million
≈ $182.72K
-23.59pp
2014-06-30 66.75% ILA49.41 Million
≈ $132.47K
ILA74.02 Million
≈ $198.45K
--
pp = percentage points

About Pluristem

TA:PSTI Israel Biotechnology & Medical Research
Market Cap
$34.49 Million
ILA12.86 Billion ILA
Market Cap Rank
#23103 Global
#319 in Israel
Share Price
ILA397.70
Change (1 day)
-4.86%
52-Week Range
ILA281.00 - ILA1497.00
All Time High
ILA72010.00
About

Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase I… Read more